Education
About Us
Working with TipRanks
Follow Us
Mymetics (MYMX)
OTHER OTC:MYMX
MYMX Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume8.00
Average Volume (3M)0.00
Market Cap
$46.00
Enterprise Value$71.68M
Total Cash (Recent Filing)$62.00K
Total Debt (Recent Filing)$75.11M
Price to Earnings (P/E)―
Beta0.65
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-82.31
Shares Outstanding151,879
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio108.11
Price to Book (P/B)-262.28
Price to Sales (P/S)5673591.92
P/FCF Ratio-10.08K
Enterprise Value/Market Cap1.56M
Enterprise Value/Revenue199.31
Enterprise Value/Gross Profit-94.07
Enterprise Value/Ebitda-8.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MYMX FAQ
What was Mymetics’s price range in the past 12 months?
Mymetics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Mymetics’s market cap?
Mymetics’s market cap is $46.00.
When is Mymetics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mymetics’s earnings last quarter?
Currently, no data Available
Is Mymetics overvalued?
According to Wall Street analysts Mymetics’s price is currently Overvalued.
Does Mymetics pay dividends?
Mymetics does not currently pay dividends.
What is Mymetics’s EPS estimate?
Mymetics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mymetics have?
Mymetics has 151,879 shares outstanding.
What happened to Mymetics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mymetics?
Currently, no hedge funds are holding shares in MYMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mymetics
Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Technical Analysis
―
Scinai Immunotherapeutics
―
Universe Pharmaceuticals
―
Dermata Therapeutics
―
Bluejay Diagnostics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.72% Other Institutional Investors
99.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---